Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: NanoViricides is a development-stage biopharmaceutical company focused on discovering, developing, and commercializing nanomedicine therapeutics for viral diseases. The company utilizes proprietary "nanoviricide" technology (TheraCour platform) to create drugs that bind to and destroy virus particles. The company has no commercial products and has not generated any revenue to date.
Key Financial Metrics
| Metric | Year Ended June 30, 2011 | Year Ended June 30, 2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,477,165) | $(4,744,208) |
| Research & Development Expenses | $4,155,846 | $3,367,409 |
| General & Administrative Expenses | $2,273,609 | $1,735,066 |
| Cash and Cash Equivalents (Ending) | $9,224,023 | $6,955,733 |
| Accumulated Deficit | $(23,216,909) | $(16,739,743) |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $1.73 million (36%) compared to the prior year, driven by higher R&D and G&A expenses.
- R&D Spend Increase: R&D expenses rose by $788,437 (23%) due to the development of additional drug candidates and increased payroll.
- G&A Spend Increase: G&A expenses increased by $538,543 (31%), primarily due to the recognition of fair value compensation paid in preferred and common stock.
- Financing Activity: The company successfully raised capital through the sale of Series B Convertible Preferred Stock. As of the filing date, the company had raised approximately $25 million in gross proceeds from these sales (including subsequent events), significantly improving liquidity compared to the prior year.
Guidance, Outlook, and Management Commentary
Outlook and Liquidity: Management estimates that current cash reserves, combined with recent financing, are sufficient to fund operations for approximately 18 months (through December 31, 2012). The company anticipates needing an additional $10 million to $15 million over the next 18 months to complete toxicology studies and file an Investigational New Drug (IND) application with the FDA.
Key Milestones:
- FluCide (Influenza): A clinical candidate (NV-INF-1) was declared subsequent to the fiscal year end. The company is preparing a pre-IND application for the FDA.
- HIVCide (HIV): Animal studies indicated efficacy equal to or better than standard HAART therapy with sustained viral load suppression after dosing ceased.
- Other Programs: Progress continues on eye drops for viral conjunctivitis, HerpeCide (herpes), and DengueCide.
Risks and Contingencies:
- Capital Requirements: The company has no revenue and relies entirely on equity financing. Failure to raise additional capital could force a reduction in R&D or cessation of operations.
- Regulatory Approval: All products are in pre-clinical stages. There is no assurance that the drugs will be safe, effective, or receive FDA approval.
- Internal Controls: The company identified a material weakness in internal control over financial reporting due to the lack of an audit committee and independent directors with financial expertise.
- Related Party Transactions: The company relies on TheraCour Pharma, Inc. (controlled by the President/Chairman) for core technology licensing and manufacturing, creating potential conflicts of interest.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the 18-month cash runway estimate given the high burn rate and potential for increased capital costs for cGMP manufacturing.
- Pre-IND Status: Confirm the timeline and specific requirements for the pre-IND filing for the FluCide candidate (NV-INF-1).
- Related Party Agreements: Review the terms of the license agreement with TheraCour Pharma, Inc., specifically regarding development fees, royalties, and the exclusive right to manufacture nanomicelles.
- Internal Control Remediation: Assess the progress made in establishing an audit committee and appointing independent directors to address the material weakness in financial reporting.
- Financing Terms: Examine the conversion terms of the Series B Convertible Preferred Stock to understand potential dilution to common shareholders.